Iproclozide

Iproclozide
Clinical data
Routes of
administration
Oral
ATC code N06AF06 (WHO)
Legal status
Legal status
  • Uncontrolled
Identifiers
CAS Number 3544-35-2 YesY
PubChem (CID) 19063
ChemSpider 17998 YesY
UNII 1II9D6CB3J YesY
KEGG D07338 YesY
ChEMBL CHEMBL91238 YesY
ECHA InfoCard 100.020.536
Chemical and physical data
Formula C11H15ClN2O2
Molar mass 242.70 g/mol
3D model (Jmol) Interactive image
  (verify)

Iproclozide (trade names Sursum, Sinderesin) is an irreversible and selective monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class that was used as an antidepressant, but has since been discontinued.[1] It has been known to cause fulminant hepatitis and there have been at least three reported fatalities due to administration of the drug.[2][3]

See also

References

  1. Suerinck A, Suerinck E (1966). "[Depressive states in a sanatorium milieu and monoamine oxidase inhibitors. (Therapeutic results by the combination of iproclozide and chlordiazepoxide). Apropos of 146 cases]". Journal de médecine de Lyon. 47 (96): 573–586. PMID 5930723.
  2. Pessayre D, de Saint-Louvent P, Degott C, Bernuau J, Rueff B, Benhamou JP (1978). "Iproclozide fulminant hepatitis. Possible role of enzyme induction.". Gastroenterology. 75 (3): 492–496. PMID 680506.
  3. Neil Kaplowitz; Laurie D. DeLeve (2003). Drug-induced liver disease. Informa Health Care. p. 455. ISBN 0-8247-0811-3. ISBN 9780824708115.


This article is issued from Wikipedia - version of the 9/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.